Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche Won’t Extend Its Bid For Illumina

by Michael McCoy
April 23, 2012 | A version of this story appeared in Volume 90, Issue 17

Roche says it has decided not to extend its tender offer for the gene-sequencing company Illumina beyond April 20. The decision follows voting results from Illumina’s annual meeting showing that stockholders rejected Roche proposals related to its $6.8 bil­lion bid for Illumina. Roche CEO Severin Schwan says the firm will consider other options to expand its position in diagnostics. Illumina CEO Jay T. Flatley says his firm will return its focus to expansion.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.